Three-year outcomes of transcatheter aortic valve implantation for bicuspid versus tricuspid aortic stenosis-Reference-Cited by-同舟云学术

Three-year outcomes of transcatheter aortic valve implantation for bicuspid versus tricuspid aortic stenosis

Published:2022-06 Issue:3 Volume:18 Page:193-202
ISSN:1774-024X
Container-title:EuroIntervention
language:
Short-container-title:

Author:

Zhou Dao,Yidilisi Abuduwufuer,Fan Jiaqi,Zhang Yebei,Dai Hanyi,Zhu Gangjie,Guo Yuchao,He Yuxin,Zhu Qifeng,Lin Xinping,Li Huajun,Jiang Jubo,Ng Stella,Li Cheng,Ren Kaida,Wang Lihan,Liu Xianbao,Wang Jian’an

Publisher

Europa Digital & Publishing

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. 2017 ESC/EACTS Guidelines for the management of valvular heart disease

2. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

3. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients

4. The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2020 Update on Outcomes and Research

5. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcatheter Aortic Valve Implantation (TAVI) in Bicuspid Aortic Valve Disease: A Systematic Review;Cardiology in Review;2024-09-05

2. Sex differences in transcatheter aortic valve replacement outcomes among patients with bicuspid aortic stenosis;Heart & Lung;2024-09

3. JenaValve Trilogy system: The saga of transcatheter interventions for aortic regurgitation has just begun;Catheterization and Cardiovascular Interventions;2024-08-18

4. Comparison of downsizing strategy (HANGZHOU Solution) and standard annulus sizing strategy in type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement: Rationale and design of a randomized clinical trial;American Heart Journal;2024-08

5. 3-Year Outcomes From the Evolut Low Risk TAVR Bicuspid Study;JACC: Cardiovascular Interventions;2024-07